Product Information
FENOFIBRATE 145 MG TABLET is a generic product labeled by Aurobindo Pharma Limited, priced at $0.1196 per EA under NDC 65862076990. Its NADAC has been published 478 times since Aug 9, 2017.
FDA first approved this application on May 5, 2016. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
145 mg/1
Manufacturer
Aurobindo Pharma LimitedNDC
65862076990
Classification
Generic
Dosage Form
TABLET, COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
FENOFIBRATEApproval Type
Generic (ANDA)
FDA Application
ANDA205118FDA Approved
5/5/2016
TE Code
AB
On Market Since
5/5/2016
Pharmacological Classes
Price Statistics
The NADAC for FENOFIBRATE 145 MG TABLET has been published 478 times since Aug 9, 2017, and over the history we have for it it has declined 78.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1196 per EA |
|---|---|
| All-time high | $0.5552 (Aug 16, 2017) |
| All-time low | $0.1088 (Nov 20, 2024) |
| 52-week high | $0.1214 |
| 52-week low | $0.1130 |
| Median price | $0.1661 |
| Average price | $0.2019 |
| Largest weekly change | +29.9% (Sep 23, 2020) |
| Weeks tracked | 478 |
| Tracking since | Aug 9, 2017 |
Generic Alternatives
The matcher finds 6 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Aurobindo Pharma Limited manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Fenofibrate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Peroxisome Proliferator Receptor alpha Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of FENOFIBRATE 145 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for FENOFIBRATE 145 MG TABLET, manufactured by Aurobindo Pharma Limited, is $0.1196 per EA (NDC 65862076990), effective Sep 30, 2026.
How has the price of FENOFIBRATE 145 MG TABLET changed over time?
Over the history we have for it, the NADAC for FENOFIBRATE 145 MG TABLET has declined 78.5%. It has been tracked across 478 weekly CMS publications since Aug 9, 2017.
What are the highest and lowest recorded NADAC prices for FENOFIBRATE 145 MG TABLET?
Since Aug 9, 2017, the NADAC for FENOFIBRATE 145 MG TABLET has ranged from a low of $0.1088 (Nov 20, 2024) to a high of $0.5552 (Aug 16, 2017), with a median of $0.1661 per EA.
Are there cheaper alternatives to FENOFIBRATE 145 MG TABLET?
6 manufacturers publish a NADAC-priced product with the same active ingredient and strength as FENOFIBRATE 145 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures FENOFIBRATE 145 MG TABLET?
FENOFIBRATE 145 MG TABLET (NDC 65862076990) is labeled by Aurobindo Pharma Limited, and CMS classifies it as a generic product.